Avid Bioservices Inc (CDMO)

[sunstar]

On the contrary, Peregrine has expressed confidence that they will completely enrol the 600 patient phase3 NSCLC trial in twenty-four months or less. As we also are aware, there are two scheduled early look-ins that could offer early bavituximab commercialization through an accelerated approval, AA. We now have fast track! Recall that bavituximab actually doubled overall survival to patients in this very difficult advanced lung cancer indication in the phase2 trial.

You should know that the ISTs are not carried out by Peregrine, but by university investigators and independent clinics. These ISTs do their own enrolling.

CEO King's RBC statement that there are now quite a few collaborations ongoing in combination immunotherapy studies may, in fact, be indicating the pathway forward to partnerships or a merger/acquisition. If a combination of bavituximab and your company's anti-PD-1 or other immuno mAb, shows a 100% response rate, and a doubling or tripling of cancer survivors, maybe you want to make Peregrine an offer that won't be refused before another company does. What are prevalent cures in cancer worth to BPs?

As to Geo's comments, I don't think the current studies combining bavi with other immunotherapies in the pre-clinical setting, unlike human trials, are very costly at all. And there should be no worries about finding plenty of willing volunteers for any of the pre-clinical collaboration studies.

IMO

sunstar